{'en': 'Scientists manage to interrupt type 1 diabetes (study)', 'es': 'Científicos logran interrumpir la diabetes tipo 1 (Estudio)'} Image

Scientists manage to interrupt type 1 diabetes (study)

fer's profile photo   01/28/2016 6:28 p.m.

  
fer
01/28/2016 6:28 p.m.

An important step towards the cure of type 1 diabetes has occurred when trying a technique that allows beta cells (insulin producers) from the attack of the immune system.

The formula of the researchers of the Koch Institute of the MIT and the Harvard Institute of stem cells, in the US, was successfully tested in laboratory mice, in which the disease was extinguished for six months.

This discovery has the potential to provide the diabetic people of a new pancreas protected from the immune system, which will allow blood sugar to be controlled without medication.At least this is the dream, ”explained Dr. Daniel Anderson, Professor of Biology at MIT.

With the new technique, in which stem cells that recreate the function of beta cells are used, this system will no longer be necessary if successful in humans.The study showed that after the implantation in mice, the cells immediately began to produce insulin in response to blood glucose levels and were able to maintain it.

"When beta cells are normally working, they are part of an exquisitely refined system, precisely providing the amount of insulin that the body needs," said Harvard Gazette.

According to this medium, this bioengineering work by professors Daniel Anderson and Robert Langer brings the promise of a possible cure for type 1 diabetes at a short distance.

“This discovery has the potential to provide the diabetic people of a new pancreas protected from the immune system, which will allow blood sugar to be controlled without medication.At least this is the dream, ”explained Dr. Daniel Anderson, Professor of Biology at MIT.

"We are very happy with this new technology and we are working hard to advance to the clinical (phase)," he added.

The work was published Monday in the magazines Nature Medicine and Nature Biotechnology, and represent almost eight years of work.

Researchers at the University of Illinois, from the Boston Children's Hospital and the University of Massachusetts also participated in the research.

Diabetes Tipo 1 desde 1.998 | FreeStyle Libre 3 | Ypsomed mylife YpsoPump + CamAPS FX | Sin complicaciones. Miembro del equipo de moderación del foro.

Autor de Vivir con Diabetes: El poder de la comunidad online, parte de los ingresos se destinan a financiar el foro de diabetes y mantener la comunidad online activa.

  
Artorias
01/28/2016 6:51 p.m.

From this I have already read and paint very well, but many years remain until serious studies begin with humans.The encapsulated beta cells is something closest.

No signature configured, add it on your user's profile.
  
aaandres
01/29/2016 9:48 a.m.

And I say ... wouldn't it be easier for them to find a pill to become mice?We would have a hundred priests for diabetes!

Padre de Andrés, 17 años. Debut: septiembre de 2011.
Levemir (30ud. mañana y 24ud. noche) y Novorapid (en desayuno, comida, merienda y cena 40ud aprox - 24HC/día).
Medidor continuo DEXCOM G4 desde julio 2014
Hemo: 6.2 (Sept. 2013), 7.0 (Dic. 2013), 6.9 (Marzo 2014), 6,6 (Junio 2014), 6,7 (Sept. 2014), 7,0 (Dic. 2014), 7,7 (Mar 2015), 6,9 (Jul. 2015), 7,0 (Sept 2015), 7,4 (Dic 2015), 6,8 (Mar 2016), 6,6 (Julio 2016), 6,8 (Octubre2016)... 7,0 (Mar 2018)

  
fer
01/29/2016 11:03 a.m.

aaandres said:
and I say ... wouldn't it be easier for them to find a pill to become mice?We would have a hundred priests for diabetes!

:)) :)) :)) :)) You can see that some mice live better than us!: P

Diabetes Tipo 1 desde 1.998 | FreeStyle Libre 3 | Ypsomed mylife YpsoPump + CamAPS FX | Sin complicaciones. Miembro del equipo de moderación del foro.

Autor de Vivir con Diabetes: El poder de la comunidad online, parte de los ingresos se destinan a financiar el foro de diabetes y mantener la comunidad online activa.

Join the Discussion!

To participate in this thread, please register or log in.